Enanta Pharmaceuticals (ENTA) Share-based Compensation (2012 - 2026)

Enanta Pharmaceuticals' Share-based Compensation history runs 15 years deep, the most recent figure standing at $24.9 million for Q1 2026.

• Quarterly Share-based Compensation rose 431.19% year-over-year to $24.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.9 million (down 41.12% YoY) and the FY2025 annual result came in at $18.8 million, down 39.31% from the prior year.
• Share-based Compensation was $24.9 million for Q1 2026 at Enanta Pharmaceuticals, up from $24.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $26.5 million in Q3 2024 and bottomed at $4.7 million in Q1 2025.
• A 5-year average of $11.7 million and a median of $7.1 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation fell 24.47% — and 2026, when it soared 431.19%.
• Enanta Pharmaceuticals' Share-based Compensation stood at $7.1 million in 2022, then jumped by 245.09% to $24.6 million in 2023, then plunged by 77.0% to $5.7 million in 2024, then jumped by 326.99% to $24.2 million in 2025, then climbed by 2.93% to $24.9 million in 2026.
• Business Quant data shows ENTA's Share-based Compensation at $24.9 million in Q1 2026, $24.2 million in Q2 2025, and $4.7 million in Q1 2025.